Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations

Venetoclax and azacitidine combination therapy (VEN+AZA) is a promising novel therapy for elderly or unfit patients with acute myeloid leukemia (AML). Recently, VEN+AZA with subsequent allo-hematopoietic stem cell transplantation has been reported, and human leukocyte antigen-haploidentical peripheral blood stem cell transplantation using posttransplant cyclophosphamide (PTCy-haplo-PBSCT) from related donors appears to be a suitable option. Here, we report two elderly patients with refractory AML harboring an IDH2 mutation, who were successfully treated with VEN+AZA bridged to PTCy-haplo-PBSCT. This report suggests the efficacy and safety of VEN+AZA as a bridging treatment for PTCy-haplo-PBSCT in refractory AML.

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations ; volume:16 ; number:1 ; year:2023 ; pages:999-1006 ; extent:8 ; Case reports in oncology ; 16, Heft 1 (2023), 999-1006 (gesamt 8)

Contributors, Places and Time

• Creator: Daido, Yusuke ; Sugiura, Hiroyuki ; Ishikawa, Tatsunori ; Kuroi, Taiga ; Okamoto, Sachiyo ; Nomura, Naho ; Masunari, Taro ; Sezaki, Nobuo ; Nannya, Yasuhito ; Ogawa, Seishi ; Tanimoto, Mitsune

Further information

• DOI: 10.1159/000533749
• URN: urn:nbn:de:101:1-2023122723574934271254
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 15.08.2025, 7:24 AM CEST